Ontology highlight
ABSTRACT:
PROVIDER: PRJNA577644 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR10279220.fastq.gz | Fastqsanger.gz | |||
| SRR10279220_1.fastq.gz | Fastqsanger.gz | |||
| SRR10279220_2.fastq.gz | Fastqsanger.gz | |||
| SRR10279221.fastq.gz | Fastqsanger.gz | |||
| SRR10279221_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 72 |
Similar Datasets
Project description:The Influenza H3N2 human challenge model has been described in detail previously5. Briefly, 20 healthy volunteers were inoculated intranasally with a standardized dose of Influenza A virus (A/Belgium/4217/2015(H3N2)) under quarantine conditions. From 24 hours after inoculation, virus was quantified by PCR in nasal lavage samples obtained at 12 hourly intervals. Participants were ascertained to have replicative viral infection if found to have consecutive positive PCR tests at least 24 hours after challenge. Blood samples for RNA sequencing were collected into PAXgene tubes before virus challenge and days 1, 2, 3, 7, 10, 14, and 28 after challenge. These were stored at -80°C until processing
2025-05-26 | E-MTAB-13041 | biostudies-arrayexpress
Project description:Despite increases in vaccination coverage, reductions in influenza-related mortality have not been observed. Better vaccines are therefore required and influenza challenge studies can be used to test the efficacy of new vaccines. However, this requires the accurate post-challenge classification of subjects by outcome, which is limited in current methods that use artificial thresholds to assign “symptomatic” and “asymptomatic” phenotypes. We present data from an influenza challenge study in which 22 healthy adults (11 vaccinated) were inoculated with H3N2 influenza (A/Wisconsin/67/2005). We generated genome-wide gene expression data from peripheral blood taken immediately before the challenge and at 12, 24, and 48 hours post-challenge. Variation in symptomatic scoring was found among those with laboratory confirmed influenza. By combining the dynamic transcriptomic data with the clinical parameters this variability can be reduced. We identified four subjects with severe laboratory confirmed flu that show differential gene expression in 1,103 probes 48 hours post-challenge compared to the remaining subjects. We have further reduced this profile to 6 genes that can be used to define these subjects. We have used this gene set to predict symptomatic infection from an independent study. This analysis gives further insight into host-pathogen interactions during influenza infection. However, the major potential value is in the clinical trial setting by providing a more quantitative method to better classify symptomatic individuals post influenza challenge. Twenty two healthy volunteers were enrolled for an influenza challenge study. Eleven were vaccinated thirty days before challenge with H3N2 influenza. Whole blood was collected in PAXgene tubes prior to influenza challenge and then at three further timepoints (12, 24 and 48 hours post-challenge).
2014-11-06 | E-GEOD-61754 | biostudies-arrayexpress
Project description:The uploaded data has been generated from the analysis of nasal scrape samples from two clinical studies registered on ClinicalTrials.gov with identifier ID NCT02755948 and NCT04204993. Primary objectives were to establish the human infection challenge model using a novel H3N2 influenza A virus (IAV, influenza A/Belgium/4217/15) at Imperial College London and to test the hypothesis that influenza lead to quantitative and functional differences in innate and T-cell responses between infected, uninfected, symptomatic and asymptomatic participants. The data is to remain private until the publishing of the relative results.
2026-07-01 | E-MTAB-13038 | biostudies-arrayexpress
Project description:In this study, we performed a miRNA global profiling in human lung epithelial cells (A549) infected by two different subtypes of human influenza A viruses (H1N1 and H3N2).
2013-04-03 | GSE42003 | GEO
Project description:We aimed to test the hypothesis that influenza infection of healthy adults alters whole blood mycobacterial control through modulation of anti-mycobacterial immune responses. We employed a whole blood mycobacterial growth inhibition assay within the framework of a human influenza challenge study. We utilised a recombinant reporter strain of mycobacteria, Mycobacterium bovis Bacille Calmette Guerin (BCG) lux, whose luminescence provides a quantitative read-out of live mycobacteria present. Volunteers were challenged with Influenza A (H3N2) virus and infection confirmed by qPCR of nasal lavage samples. Blood aliquots, taken from participants before and after influenza infection, were infected with BCG lux and incubated for up to 72 hours (0, 6, 24, 72 h). BCG-uninfected blood aliquots were also incubated. Whole blood mycobacterial growth and transcriptomic, cytokine and cellular responses to mycobacterial infection were measured in parallel and compared in the same subjects, before versus after influenza infection.
2026-06-11 | E-MTAB-15137 | biostudies-arrayexpress
Project description:Despite increases in vaccination coverage, reductions in influenza-related mortality have not been observed. Better vaccines are therefore required and influenza challenge studies can be used to test the efficacy of new vaccines. However, this requires the accurate post-challenge classification of subjects by outcome, which is limited in current methods that use artificial thresholds to assign “symptomatic” and “asymptomatic” phenotypes. We present data from an influenza challenge study in which 22 healthy adults (11 vaccinated) were inoculated with H3N2 influenza (A/Wisconsin/67/2005). We generated genome-wide gene expression data from peripheral blood taken immediately before the challenge and at 12, 24, and 48 hours post-challenge. Variation in symptomatic scoring was found among those with laboratory confirmed influenza. By combining the dynamic transcriptomic data with the clinical parameters this variability can be reduced. We identified four subjects with severe laboratory confirmed flu that show differential gene expression in 1,103 probes 48 hours post-challenge compared to the remaining subjects. We have further reduced this profile to 6 genes that can be used to define these subjects. We have used this gene set to predict symptomatic infection from an independent study. This analysis gives further insight into host-pathogen interactions during influenza infection. However, the major potential value is in the clinical trial setting by providing a more quantitative method to better classify symptomatic individuals post influenza challenge.
2014-11-06 | GSE61754 | GEO
Project description:Airway epithelial cells are the initial site of infection with influenza viruses. The innate immune responses of airway epithelial cells to infection have the potential to limit virus replication and induce effective adaptive immune responses. However, relatively little is known about the importance of this innate anti-viral response to infection. Avian influenza viruses are a potential source of future pandemics, therefore it is critical to examine the effectiveness of the host anti-viral system to different influenza viruses. We used a human influenza (H3N2) and a low pathogenic avian influenza (H11N9) to assess and compare the anti-viral responses of bronchial epithelial cells (BECs). After infection, the H3N2 virus replicated more effectively than the H11N9 strain in BECs. This was not due to differential expression of different sialic acid residues on BECs but was attributed to the interference of the host anti-viral responses by H3N2. The H3N2 strain induced a delay in anti-viral signaling and impaired release of type I and type III interferons (IFNs) compared to the H11N9 virus. We then transfected the gene encoding for non-structural (NS) 1 protein into the BECs and the H3N2 NS1 induced a greater inhibition of anti-viral responses compared to the H11N9 NS1. While the low pathogenic avian influenza virus was capable of infecting BECs, the human influenza virus replicated more effectively than avian influenza virus in BECs and this may be at least in part due to a differential ability of the two NS1 proteins to inhibit anti-viral responses. This suggests that the subversion of human anti-viral responses may be an important requirement for influenza viruses to adapt to the human host and induce disease.
2009-12-19 | GSE19580 | GEO
Project description:Fine particulate matter (PM2.5) pollution remains a major threat to public health. As the physical barrier against inhaled air pollutants, airway epithelium is a primary target for PM2.5 and influenza viruses, two major environmental insults. Recent studies have shown that PM2.5 and influenza viruses may interact to aggravate airway inflammation, an essential event in the pathogenesis of diverse pulmonary diseases. Airway epithelium plays a critical role in lung health and disorders. Thus far, the mechanisms for the interactive effect of PM2.5 and the influenza virus on gene transcription of airway epithelial cells have not been fully uncovered. In this present pilot study, the transcriptome sequencing approach was introduced to identify responsive genes following individual and co-exposure to PM2.5 and influenza A (H3N2) viruses in a human bronchial epithelial cell line (BEAS-2B). Enrichment analysis revealed the function of differentially expressed genes (DEGs). Specifically, the DEGs enriched in the xenobiotic metabolism by the cytochrome P450 pathway were linked to PM2.5 exposure. In contrast, the DEGs enriched in environmental information processing and human diseases, such as viral protein interaction with cytokines and cytokine receptors and epithelial cell signaling in bacterial infection, were significantly related to H3N2 exposure. Meanwhile, this study found that co-exposure to PM2.5 and H3N2 may affect G protein-coupled receptors on the cell surface by modulating Ca2+. Thus, the results from this study provides insights into PM2.5- and influenza virus-induced airway inflammation and potential mechanisms
2023-11-15 | GSE244959 | GEO